AU4787693A - Protein kinase inhibitors and related compounds combined with taxol - Google Patents

Protein kinase inhibitors and related compounds combined with taxol

Info

Publication number
AU4787693A
AU4787693A AU47876/93A AU4787693A AU4787693A AU 4787693 A AU4787693 A AU 4787693A AU 47876/93 A AU47876/93 A AU 47876/93A AU 4787693 A AU4787693 A AU 4787693A AU 4787693 A AU4787693 A AU 4787693A
Authority
AU
Australia
Prior art keywords
alkyl
compound
tumors
taxol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47876/93A
Other languages
English (en)
Inventor
Irene Abraham
Paul A. Aristoff
Harvey I Skulnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU4787693A publication Critical patent/AU4787693A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU47876/93A 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol Abandoned AU4787693A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92919992A 1992-08-12 1992-08-12
US929199 1992-08-12
PCT/US1993/007054 WO1994004541A2 (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol

Publications (1)

Publication Number Publication Date
AU4787693A true AU4787693A (en) 1994-03-15

Family

ID=25457472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47876/93A Abandoned AU4787693A (en) 1992-08-12 1993-07-30 Protein kinase inhibitors and related compounds combined with taxol

Country Status (6)

Country Link
EP (1) EP0655066A1 (ko)
JP (1) JPH08500112A (ko)
KR (1) KR950702994A (ko)
AU (1) AU4787693A (ko)
CA (1) CA2140653A1 (ko)
WO (1) WO1994004541A2 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
AU6657596A (en) * 1995-07-31 1997-02-26 Ciba-Geigy Ag Trindene compounds
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7820718B1 (en) * 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
WO2004026319A2 (en) * 2002-09-17 2004-04-01 Centre National De La Recherche Scientifique Pharmaceutical compositions increasing camp useful for the treatment of cancers
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
WO2005014003A1 (en) * 2003-07-23 2005-02-17 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
CA2479696A1 (en) 2003-11-11 2005-05-11 Amadeo Parissenti Use of calphostin-c to treat drug-sensitive tumor cells
EP1924267A2 (en) * 2005-08-09 2008-05-28 Johannes Gutenberg-Universität Mainz Staurosporine derivatives for treating non-small cell lung cancer
KR102271848B1 (ko) * 2013-11-01 2021-07-01 피트니 파마슈티컬스 피티와이 리미티드 암 치료용 약학적 배합물
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体

Also Published As

Publication number Publication date
JPH08500112A (ja) 1996-01-09
CA2140653A1 (en) 1994-03-03
WO1994004541A2 (en) 1994-03-03
WO1994004541A3 (en) 1994-06-09
EP0655066A1 (en) 1995-05-31
KR950702994A (ko) 1995-08-23

Similar Documents

Publication Publication Date Title
AU4787693A (en) Protein kinase inhibitors and related compounds combined with taxol
FI91764C (fi) Analogiamenetelmä asyylideoksiribonukleosidijohdannaisten valmistamiseksi
IL89503A (en) Taxol derivatives, pharmaceutical compositions containing the same and process for the preparation thereof
KR20020082458A (ko) 탁산 프로드럭
JP5087052B2 (ja) 改良された治療剤
HU224918B1 (en) Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
CN112245591A (zh) 化疗药物-低氧激活前药一体化前药自组装纳米粒的构建
US20030176496A1 (en) N-substituted Dithiocarbamates for the Treatment of Biological Disorders
PL182204B1 (en) Derivatives of colchicine and their tharapeutic application
US7820839B2 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
WO2017142269A1 (ko) 신규한 인돌 유도체 및 이를 포함하는 항암 조성물
CN107513089B (zh) 一种新型胞苷衍生物二聚体及其应用
CN111518157B (zh) 一种雷公藤甲素衍生物及其制备方法和应用
MUNAKATA et al. Some structure-activity relationships for bactobolin analogs in the treatment of mouse leukemia P388
US20040122081A1 (en) Pharmaceutical compositions and methods of using taxane derivatives
US20050054716A1 (en) Pharmaceutical compositions and methods of using taxane derivatives
KR20090038902A (ko) 에포틸론 ｂ의 결정 형태 및 제약 조성물에서의 용도
RU2200157C2 (ru) Пиридинкарбоксамидины, способ их получения и фармацевтическая композиция на их основе
ES2307253T3 (es) Analogos de la wortmannina y procedimientos de uso de los mismos.
US20070286906A1 (en) Dihydrobenzoquinone compounds
CN117427176A (zh) 一种药物偶联物及其应用
TWI286552B (en) C10 carbonate substituted taxanes
WO1996018401A1 (en) Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
CN115181154A (zh) Pyxinol酰胺衍生物及其制备方法以及在药物领域中的应用
CN115974890A (zh) 石蒜碱衍生物及其制备方法和在制备抗肿瘤药物中的应用